Cannim has taken three alternative routes to enter its market: direct, through alliances, and through channels. We have had success in each of these approaches and will expand on these in the future. Cannim has also developed leading alliances with research institutes and other medical cannabis groups to provide a greater network of collaborative support and research to position it as a a global leader.
This gives us direct access to the market. We have signed an off-take agreement with one of the 8 original licensees in Israel. The agreement specifies initial quantities with pricing at market rates.
We have signed a teaming agreement with the oldest pharmaceutical company in Jamaica to co-develop medicinal cannabis products and to be their exclusive supplier of cannabis. We will distribute through their channels to 20 countries including UK, Canada and the USA.
We have signed an off-take agreement with an emerging specialist cannabis group which has been setting up distribution channels in Europe for more than two years. They have been interacting with governments, national pharmacy chains and associations.